"It's part of a global power shift that's seen China emerge as a powerhouse in AI, chemistry and other areas, Andrei Iancu, undersecretary of commerce for intellectual property in the first Trump administration, told Axios. "Any way you cut it, any way you measure, they're basically pointing in the same direction: China taking the lead, already leading, or knocking on the door in these various areas," Iancu said."
"Steep Food and Drug Administration staff cuts, the Trump administration's proposed 40% budget reduction for National Institutes of Health and its termination of $500 million for mRNA vaccine development could chill investor enthusiasm and fuel an exodus of research talent. "This current retrograde step by the U.S. will allow others to catch up and likely pull ahead in the context of vaccines," Robin Shattock, professor of mucosal infection and immunity at Imperial College London, told Inside Higher Ed."
China has emerged as a major technology and biotech powerhouse, expanding strength in AI, chemistry and drug development. China-sourced antibodies, heart treatments and other drug candidates will account for almost 40% of licensing deals this year, up from less than 3% five years ago. More than $150 billion has been committed by major pharmaceutical companies to license assets from Chinese sources in the past five years, and some company pipelines now include roughly 10% Asia-origin assets. Concurrent U.S. cuts and freezes in federal biomedical funding, FDA staffing reductions and scaled-back vaccine investment could chill investors and drive research talent abroad, potentially allowing other countries to catch up or surpass U.S. capabilities in vaccines and therapeutics.
Read at Axios
Unable to calculate read time
Collection
[
|
...
]